Sung Ju Moon

Title: Innovations by Sung Ju Moon in Antibody Drug Conjugates

Introduction

Sung Ju Moon is an accomplished inventor based in Santa Monica, CA (US). He has made significant contributions to the field of cancer treatment through his innovative work on antibody drug conjugates (ADCs). With a total of 2 patents, his research focuses on developing therapeutic compositions that target specific proteins associated with cancer.

Latest Patents

Sung Ju Moon's latest patents involve antibody drug conjugates (ADCs) that bind to FLT3 proteins. These ADCs are designed to target FLT3 protein and its variants, which exhibit a distinct and limited expression pattern in normal adult tissues. However, FLT3 is aberrantly expressed in various cancers, making these ADCs a promising therapeutic option for cancer treatment. The detailed descriptions of these inventions highlight their potential to provide effective solutions in oncology.

Career Highlights

Sung Ju Moon is currently associated with Agensys, Inc., where he continues to advance his research in antibody drug conjugates. His work has garnered attention for its innovative approach to targeting cancer cells while minimizing effects on normal tissues. His contributions to the field have positioned him as a notable figure in cancer research.

Collaborations

Sung Ju Moon collaborates with talented professionals in his field, including Nandini Rudra-Ganguly and Christine Lowe. These collaborations enhance the research environment and foster innovation in developing new therapeutic strategies.

Conclusion

Sung Ju Moon's work in developing antibody drug conjugates represents a significant advancement in cancer treatment. His innovative approach and collaboration with other experts in the field continue to pave the way for new therapeutic options.